In addition, dinaciclib (CDK inhibitor), idasanutlin (MDM2 inhibitor inhibiting cell proliferation and inducing apoptosis), and romidepsin (HDAC inhibitor) were also very effective to reduce the T-PLL cancer cell viability, but these three drugs were only tested for the first T-PLL cohort. This evidence concerns the gene HDAC9 and cancer.